Why TTRX Stock dropped -2.70% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, TTRX scores 39 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars, the weakest area is insider conviction at 3 of 20, followed by the fundamental cash engine at 6 of 20. Those two low scores indicate that, under this framework, neither company-level cash generation nor recent insider activity provides meaningful support for the stock. The fundamental cash engine score reflects an ROIC of -28.3% and an FCF yield of -0.78%, meaning the business is currently consuming rather than producing cash relative to its market value. Whale/13F flow scores 9 of 20, indicating some institutional and options positioning activity but not enough to offset weak fundamentals. Macro regime fit scores 11 of 20 with a beta of 1.0, meaning the stock is rated as moving in line with the broader market with no additional sector-driven tailwind identified in the source data. The forensic balance sheet pillar scores 10 of 20, supported by an Altman Z of 2.5, a Piotroski F of 1 out of 9, and a debt-to-equity ratio of 0.5. The Piotroski reading is the weakest of these forensic indicators and suggests limited improvement across the standard financial-health tests.

For a prospective investor evaluating the stock today, the practical implication is that the rating frames TTRX as a high-risk, cash-consuming company whose valuation depends on future catalysts rather than current economics. Upside drivers would need to come from clinical or regulatory progress rather than earnings, and the valuation tradeoff is that the market is pricing a pipeline outcome without current cash-flow support. Investors should weigh the near-term funding runway against the timing of catalysts referenced in the news wire.

Turn Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, its market capitalization is $0.3B. The source data does not describe its specific products, customers, or revenue model. The FY 2025 and FY 2024 financials report $0.0M in revenue in both periods, indicating no reported revenue in the source data.

Per the SEC financials, the company reported operating losses in both periods, with operating income widening from $-1.8M in FY 2024 to $-5.9M in FY 2025. Margins are reported as 0% for gross, operating, and net in the market data, and ROIC is -28.3%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1 out of 9, with a debt-to-equity ratio of 0.5. Cash increased from $0.5M to $4.0M over the two reported years, while free cash flow remained negative in both periods.

• Pipeline and funding catalyst (MARKET WIRE / TradingView): An investor presentation update references a Phase 2 AD topline expected in Q1 2027 and cash runways into Q3 2027 at $10.3M. This is the most material timing item in the feed.
• Analyst rating changes (CATALYST / MarketBeat): Wall Street Zen raised TTRX to Hold, while a separate report notes a cut to Sell at Wall Street Zen. WBB Securities upgraded to Hold with a $10 price target (TradingView).
• Investor event (MARKET WIRE / Business Wire): BTIG is hosting Turn Therapeutics for a virtual fireside chat.
• Risk Watch (RISK WATCH / MarketBeat): The Sell-rating cut is flagged as a risk-watch item in the feed.
• Market action (MARKET WIRE / Yahoo Finance Canada): A general market-action item with no quantitative detail beyond the headline.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Analyst data and holder data are not available in the source data. Per the news wire, analyst rating actions include Hold upgrades from Wall Street Zen and WBB Securities (with a $10 price target), and a Sell cut from Wall Street Zen. No SEC Form 4, 13F, or Congressional trade details are provided in the holders section.

• What are the specific clinical and regulatory milestones behind the Phase 2 AD topline timing, and what is the probability-weighted outcome?
• Does the $10.3M cash runway into Q3 2027 account for planned spending, and what financing would be required afterward?
• What drove the FY 2025 operating loss increase from $-1.8M to $-5.9M?
• What is the company's debt position, given debt is reported as N/A while debt-to-equity is 0.5?
• What is the basis for the conflicting Wall Street Zen rating changes within the same news cycle?